Evidence map›Paper›PMID 38880905›Full record

ReviewJournal of nanobiotechnology2024

Nanomaterial-related hemoglobin-based oxygen carriers, with emphasis on liposome and nano-capsules, for biomedical applications: current status and future perspectives.

Kai Zhu, Lijun Wang, Yao Xiao, Xiaoyong Zhang, Guoxing You, Yuzhi Chen, Quan Wang, Lian Zhao, Hong Zhou, Gan Chen

Abstract readReview
In one paragraph

Review in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Review
  2. Review
  3. Enhanced Antibacterial Activity ofJournal of functional biomaterials · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Cocktail-style multifunctional resuscitation fluids: Where are we now in 2026?Journal of anesthesia and translational medicine · 2026
    Review
  8. Review
  9. Hemocompatibility Evaluation of PEGylated Bovine Hemoglobin.International journal of molecular sciences · 2026
    Article
  10. Review
  11. Review
  12. Review
  13. Emerging Nanoplatforms are Effective Against Tumor Hypoxia.International journal of nanomedicine · 2026
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kai Zhu *Academy of Military Medical Sciences, Beijing, 100850, China.
Lijun Wang *Academy of Military Medical Sciences, Beijing, 100850, China.
Yao XiaoAcademy of Military Medical Sciences, Beijing, 100850, China.
Xiaoyong ZhangAcademy of Military Medical Sciences, Beijing, 100850, China.
Guoxing YouAcademy of Military Medical Sciences, Beijing, 100850, China.
Yuzhi ChenAcademy of Military Medical Sciences, Beijing, 100850, China.
Quan WangAcademy of Military Medical Sciences, Beijing, 100850, China.
Lian ZhaoAcademy of Military Medical Sciences, Beijing, 100850, China. zhaolian@bmi.ac.cn.
Hong ZhouAcademy of Military Medical Sciences, Beijing, 100850, China. zhouhtt1966@163.com.
Gan ChenAcademy of Military Medical Sciences, Beijing, 100850, China. chenlzu2005@163.com.

Funding

National Natural Science Foundation of China No. 82170229
6 · The paper itself

Abstract

Oxygen is necessary for life and plays a key pivotal in maintaining normal physiological functions and treat of diseases. Hemoglobin-based oxygen carriers (HBOCs) have been studied and developed as a replacement for red blood cells (RBCs) in oxygen transport due to their similar oxygen-carrying capacities. However, applications of HBOCs are hindered by vasoactivity, oxidative toxicity, and a relatively short circulatory half-life. With advancements in nanotechnology, Hb encapsulation, absorption, bioconjugation, entrapment, and attachment to nanomaterials have been used to prepare nanomaterial-related HBOCs to address these challenges and pend their application in several biomedical and therapeutic contexts. This review focuses on the progress of this class of nanomaterial-related HBOCs in the fields of hemorrhagic shock, ischemic stroke, cancer, and wound healing, and speculates on future research directions. The advancements in nanomaterial-related HBOCs are expected to lead significant breakthroughs in blood substitutes, enabling their widespread use in the treatment of clinical diseases.

Indexed as

Blood SubstitutesHemoglobinsLiposomesNanostructuresOxygenAnimalsHumansNanocapsulesNeoplasmsShock, HemorrhagicWound HealingBlood SubstitutesHemoglobinsLiposomesNanocapsulesOxygenCancerHemoglobin-based oxygen carriers (HBOCs)Hemorrhagic shockNanomaterialsOxygen transport

Identifiers

PMID38880905
PMCPMC11180412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.